Current Research in Translational Medicine Author Guidelines
Current Research in Translational Medicine's submission process, first-decision timing, and the editorial checks that matter before peer review begins.
Readiness scan
Before you submit to Current Research in Translational Medicine, pressure-test the manuscript.
Run the Free Readiness Scan to catch the issues most likely to stop the paper before peer review.
Key numbers before you submit to Current Research in Translational Medicine
Acceptance rate, editorial speed, and cost context, the metrics that shape whether and how you submit.
What acceptance rate actually means here
- Desk rejection at Current Research in Translational Medicine accounts for a significant share of early returns.
- Scope misfit and framing problems drive most early rejections, not weak methodology.
- Papers that reach peer review face a different bar: novelty, rigor, and fit with the journal's editorial identity.
What to check before you upload
- Scope fit: does your paper address the exact problem this journal publishes on?
- Desk decisions are fast; scope problems surface within days.
- Cover letter framing: editors use it to judge fit before reading the manuscript.
How to approach Current Research In Translational Medicine
Use the submission guide like a working checklist. The goal is to make fit, package completeness, and cover-letter framing obvious before you open the portal.
Stage | What to check |
|---|---|
1. Scope | Scope check |
2. Package | Formatting check |
3. Cover letter | Editorial screening |
4. Final check | Peer review |
Quick answer: The Current Research in Translational Medicine author guidelines are on Elsevier's live Guide for Authors. The journal's official scope is not generic translational medicine: it covers clinical and basic research in hematology, immunology, hematopoietic cell transplantation, cellular therapy, and gene therapy. Before uploading, make the bridge between the evidence and that clinical or biological consequence explicit.
For adjacent preparation, use the manuscript quality check, clinical research submission checklist, and journal-selection guide.
From our manuscript review practice
The fit question is not whether a study uses the word translational. It is whether the paper links basic or clinical evidence to a defensible hematology, immunology, transplantation, cellular-therapy, or gene-therapy consequence.
Is this the right translational route?
The official journal description names a focused set of fields. That makes the manuscript's translational bridge more important than a broad statement of potential importance. A hematology cohort, immunology mechanism, transplant outcome, cellular therapy study, or gene-therapy result can fit when the paper explains what moves between basic observation, clinical question, and actionable evidence. A general biomedical paper with a distant future application should be routed against journals that actually publish its present contribution.
The practical question is: what has crossed a boundary in this manuscript? It may be a mechanistic finding interpreted against a human disease problem, a clinical observation that tests a biological hypothesis, a therapy result with a defined patient or cell population, or a reproducible method that changes how a translational question can be studied. The answer should be visible in the title, abstract, primary endpoint, and limitations, not only in the final discussion paragraph.
Manuscript center of gravity | Better first route | Decision test |
|---|---|---|
Hematology, immunology, transplantation, cellular therapy, or gene therapy with a clear translational consequence | Current Research in Translational Medicine | Does the manuscript connect the result to a concrete biological or clinical decision within the journal's remit? |
Basic mechanism with no patient, therapeutic, or disease-facing consequence yet | A specialist basic-science journal | Is the translational claim still a future hypothesis rather than a result? |
Broad clinical trial or clinical-practice result outside the named fields | A clinical specialty or general-medicine journal | Is the target reader defined by disease practice rather than translational-field scope? |
Computational model or platform with no biological or clinical validation | A methods, informatics, or domain journal | Does the validation show more than technical performance? |
What the current Elsevier guide establishes
The official guide describes a peer-reviewed, electronic journal publishing worldwide clinical and basic research in the named fields. It says the work must not have been published previously except in permitted forms such as a preprint, abstract, published lecture, academic thesis, or registered report. It also asks authors to settle the definitive author list at original submission, disclose sponsor roles where applicable, follow the journal's research-data guidance, and declare generative-AI use in manuscript preparation at submission.
The live Guide for Authors is the authority for submission mechanics, article types, file requirements, and any current portal link. Do not treat a copied template or a neighboring Elsevier journal's requirements as a substitute for the active page.
Package decision | Check in the current official guide | Why it matters |
|---|---|---|
Article type and scope | Match the study's actual evidence to the live journal remit. | A broad translational label cannot repair a field mismatch. |
Author record | Confirm author list and order before original submission. | The official guide asks for a definitive list at that stage. |
Prior dissemination | Record preprints, abstracts, theses, registered reports, and related work accurately. | Editors need a transparent publication history. |
Sponsor, data, and AI disclosures | Use the current journal and Elsevier instructions for the study's applicable disclosures. | These statements are part of an accountable translational evidence package. |
Figures and evidence tables | Keep patient, specimen, intervention, comparator, and endpoint definitions consistent. | Translational claims depend on who or what the evidence actually represents. |
Source: Current Research in Translational Medicine Guide for Authors, checked July 15, 2026.
Pre-submission checklist
- Confirm that the manuscript's field fits hematology, immunology, hematopoietic cell transplantation, cellular therapy, or gene therapy rather than merely using the phrase "translational medicine."
- Name the study population, biological system, treatment or exposure, comparator, primary endpoint, and the boundary on the conclusion.
- Verify the final author order, affiliations, corresponding author, and any sponsor-role statement before beginning the upload.
- Record preprint, conference abstract, thesis, registered-report, dataset, code, and related-paper details that the live instructions request.
- Check whether the abstract and figures distinguish a mechanistic observation, clinical association, therapeutic result, and validated translational conclusion.
- Reopen the current Elsevier page before submission to confirm article-type, portal, data, disclosure, and AI-use requirements.
Readiness check
Run the scan while Current Research in Translational Medicine's requirements are in front of you.
See how this manuscript scores against Current Research in Translational Medicine's requirements before you submit.
How this guide was reviewed
We checked the current ScienceDirect journal page and Guide for Authors. Those sources establish the scope and administrative requirements. Use this page when you need to decide whether the manuscript is ready for this specific journal, then use the readiness checks below to test whether the abstract, methods, results, and limitations tell one coherent translational story within the journal's named fields.
This guide does not infer editor behavior, acceptance rates, review times, or a universal data policy. It is for an author who needs to decide whether the present evidence, rather than a hoped-for future application, fits this journal now.
In our pre-submission review work: three translational bridges that break
In our pre-submission review work, we find that weak translational framing usually comes from an unsupported bridge, not a lack of scientific promise. What actually happens in a difficult review is that the reader must reconstruct the patient, model, endpoint, or causal link that the manuscript leaves implicit. Authors can test these specific named failure patterns before submission by reading the abstract, figure legends, patient or model definitions, and limitations as a single chain of evidence. This makes a practical difference when a paper combines laboratory and patient-facing claims, because the reader needs to see exactly which link in the translation chain has been tested.
A mechanistic finding presented as a clinical implication
Cell, tissue, or model evidence can make a strong biological contribution. It becomes a clinical implication only when the paper states the relevant patient or disease context and shows what supports the extension. If the clinical step has not been tested, describe it as the next question rather than as an established therapeutic consequence.
Check whether the abstract calibrates the translational claim.
A clinical association presented as a biological mechanism
An association in a patient cohort may identify an important translational signal, but it cannot by itself establish the pathway that produced it. Show which evidence is clinical, which is experimental, and which remaining causal step is unresolved. That distinction protects both the scientific claim and the clinical reader who needs to know what the result can change.
Check whether the methods and conclusion distinguish association from mechanism.
A therapeutic claim without a population or endpoint boundary
Cellular and gene-therapy work is especially vulnerable to a result that sounds broader than its tested population, dose, follow-up, comparator, or safety window. State those conditions near the result, not only in a supplement. A reader should be able to tell whether the work establishes feasibility, a biological signal, a clinical outcome, or a durable therapeutic effect.
Check whether the endpoint and population boundary are visible.
A practical editorial path
The journal does not provide a universal decision-time promise. Use this sequence for preparation, not as an official review calendar.
Day 0: scope and disclosure check
Confirm that the manuscript belongs in a named field and that the author, prior-publication, sponsor, data, and AI-use records are complete. Make the translational question visible before uploading the package.
Days 1 to 7: technical and scope assessment
An initial assessment can establish whether the submission package is complete and whether the work falls within the journal's hematology, immunology, transplantation, cellular-therapy, or gene-therapy remit. The early test is whether the evidence chain is understandable without guessing at the clinical or biological bridge.
Weeks 2 onward: specialist review and revision
For a paper that moves forward, reviewers can test the patient or model relevance, endpoint definition, comparator, reproducibility evidence, and claim boundary. Keep data versions, code, protocol details, consent or ethics records, and source figures traceable before a revision request arrives.
Submit if / think twice if
Submit if: the manuscript has a clear connection to one of the journal's named fields, defines the translational question, and makes the evidence boundary visible in the abstract and figures.
Think twice if: a basic result is described as clinical without human or disease-facing evidence; a patient association is described as a mechanism without a test of the pathway; or a therapy result lacks a defined population, endpoint, comparator, or follow-up boundary. Narrow the claim, strengthen the evidence, or choose a journal that fits the current contribution.
An evidence-boundary readiness check can test whether the title, abstract, methods, figures, and venue rationale use the same level of claim.
The evidence table that earns its space
Evidence problem | Weak presentation | Stronger pre-submission test | Reader consequence |
|---|---|---|---|
Translation claim | State that a laboratory result will improve care | Identify the patient, disease, intervention, or decision the evidence actually reaches | The clinical implication has an explicit boundary. |
Mechanism claim | Present a cohort association as proof of a pathway | Separate association, experimental support, and unresolved causal steps | The reader can assess what biology is established. |
Therapy result | Report a favorable response without population or follow-up context | State eligibility, comparator, endpoint, safety ascertainment, and follow-up window | The therapeutic conclusion is interpretable. |
Frequently asked questions
Use the current Elsevier Guide for Authors and its live submission link. Recheck the active journal page before upload because the portal, article-type requirements, and package fields can change.
The current official journal page describes worldwide clinical and basic research in hematology, immunology, hematopoietic cell transplantation, cellular therapy, and gene therapy. A paper should make the connection to that remit explicit.
The current Elsevier guide says previously posted work may be considered when it appeared as a preprint, abstract, published lecture, academic thesis, or registered report, subject to the journal's live policy. Verify the current wording before submission.
The current guide directs authors to Elsevier's research-data guidance and asks authors to disclose sponsor roles where applicable. It also says generative-AI use in manuscript preparation must be declared on submission. Confirm the live requirements for your article type.
Sources
Final step
Submitting to Current Research in Translational Medicine?
Run the Free Readiness Scan to see score, top issues, and journal-fit signals before you submit.
Target journal carried over: Current Research in Translational Medicine
Anthropic Privacy Partner. Your manuscript is never used to train any model.